Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study aims to make diabetes drug safer by testing ketone alarms

NCT ID NCT07225465

First seen Nov 06, 2025 · Last updated May 18, 2026 · Updated 22 times

Summary

This study tests whether a lower ketone alarm (1.0 mmol/L) is better than a higher one (1.5 mmol/L) at preventing diabetic ketoacidosis (DKA) in people with type 1 diabetes who take the drug dapagliflozin. About 115 adults will use a continuous ketone monitor and receive education on responding to alarms. The goal is to find the safest way to use this drug, which can lower blood sugar but also raises DKA risk.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Austin Health

    Heidelberg, Victoria, 3084, Australia

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Baker Heart and Diabetes Institute

    Melbourne, Victoria, 3004, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • St Vincent's Hospital Melbourne

    Fitzroy, Victoria, 3065, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Royal Melbourne Hospital

    Parkville, Victoria, 3050, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.